secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-05-12T11:33:15+00:00
Accession:  0001193125-26-218192
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI
--------------------------------------------------------------------------------

- Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.
- Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.
- Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.
- Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.
- R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/0001193125-26-218192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/mreo-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer